Oppenheimer updates 2012-2015 EPS Estimates on Alexion Pharmaceuticals (ALXN)

Following strong first quarter results driven by sales of Soliris, Oppenheimer analysts are updating their EPS estimates on Alexion Pharmaceuticals (NASDAQ: ALXN) for 2012 through 2015. The new estimates are $1.79, $2.43, $3.18 and $4.04, respectively, compared to prior estimates of $1.72, $2.38, $3.03 and $3.87.

“Soliris PNH sales remain on an upward trajectory,” says one Oppenhimer analyst. “We believe ex-US expansion and increasing PNH diagnosis will further drive Soliris sales growth. Notably, we see additional upside in PNH, as ALXN reports the disease remains underdiagnosed. Based on this, we view PNH sales as a continuing Soliris growth driver in '12 and into 1H13.”

Oppenheimer analysts have a $100 price target on ALXN and an OUTPERFORM rating.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $88.90 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)